Document:

Accelerated
Clinical Trial Agreement

 

This
Accelerated Clinical Trial (ACTA) Agreement (“Agreement”) is made as of September 12,2018 (“Effective Date”)
by and between Providence Health & Services - Washington, dba Providence Regional Medical Center Everett (“Institution”),
a non-profit corporation organized under the laws of the State of Washington, having an address at 1330 Rockefeller Avenue, Suite
440, Everett, Washington 98201, The Everett Clinic, PLLC, a Washington professional limited liability company with a place of
business at 3901 Hoyt Avenue, Everett, WA 98201 (“Clinic”), Jason Lukas, M.D., an employee of Clinic, with a place
of business at 1717 13th Street, Suite 300, Everett, Washington 98201 (“Principal Investigator”), and Cancer
Insight, LLC, a limited liability company having its principal place of business at 1422 E Grayson, 3rd Floor, San
Antonio, TX 78208 (“CRO”). CRO, Clinic, Principal Investigator, and Institution are herein referred to collectively
as “Parties.” Individually, each of CRO, Clinic, Principal Investigator, and Institution is a “Party.”

 

WHEREAS,
CRO has been engaged by BriaCell Therapeutics Corp, (the “Sponsor”) to arrange and administer a multi-center clinical
trial funded by Sponsor to determine the safety and efficacy of Sponsor’s product;

 

WHEREAS,
Sponsor is a for-profit organization that intends to conduct a sponsored multi-center clinical trial, described in 1.1 below,
involving the use of certain diagnostic(s), drug(s), devices(s), or biologic(s) provided by Sponsor and desires that Institution,
Principal Investigator, and Clinic participate in such clinical trial;

 

WHEREAS,
Institution, Clinic, Principal Investigator, Sponsor, and CRO have agreed to use the ACTA, to accelerate the process of translating
laboratory discoveries into treatments for patients, to engage communities in clinical research efforts, and to train a new generation
of clinical and translational researchers;

 

WHEREAS,
Institution and Clinic have entered into a separate Research Collaboration and Services Agreement with an effective date of
May 1, 2018, which, along with the terms of this Agreement shall govern their conduct of the Study;

 

WHEREAS,
the Institution and Clinic have appropriate facilities and personnel with the qualification, training, knowledge, and experience
necessary to conduct such a clinical trial; and

 

WHEREAS,
the Study contemplated by this Agreement is of interest and benefit to Institution, Clinic, Principal Investigator, Sponsor,
and CRO, and will further the instructional and research objectives of Institution in a manner consistent with its status as a
research and health care institution;

 

NOW,
THEREFORE, in consideration for the mutual promises made in this Agreement and for valid consideration, the Parties agree
as follows:

 

1.
Scope of Agreement

 

1.1.
Institution and Clinic will undertake a sponsored multi-center clinical trial (“Study”) described in the protocol
entitled “A Phase i/lla Rollover Study of the Whole-Cell Vaccine BriaVaxTM in Metastatic or Locally Recurrent Breast
Cancer Patients in Combination with Ipilimumab or Pembrolizumab” and having a protocol designation of BRI-ROL-001 which
is incorporated herein as Exhibit A (“Protocol”). Institution and Clinic will use its reasonable efforts to
only recruit subjects in accordance with the Protocol. The Study will be conducted by the Institution and Clinic under the direction
of Jason Lukas, M.D., an employee of the Clinic.

 

    	1

    	 

    

 

1.2.
In the event of any conflict between the terms and conditions of this Agreement and the Protocol or between this Agreement and
any of its Exhibits, the terms and conditions of the Protocol shall control with respect to matters of medicine and science, and
the terms of this Agreement shall control with respect to all other matters.

 

1.3.
Unless otherwise agreed to by the Parties, Sponsor and/or CRO will provide to Institution and/or Clinic on a timely basis, without
charge, the required quantities of properly-labeled Sponsor drug(s) or biologics(s) (“Study Drug”) and/or device(s)
(“Study Device”) and other materials (e.g., Investigator’s Brochure, handling and storage instructions, and,
if applicable, placebo) necessary for Institution and Clinic to conduct the Study in accordance with the Protocol. Unless stated
otherwise in writing by Sponsor, all such items are and will remain the sole property of Sponsor until administered or dispensed
to Study subjects during the course of the Study. Receipt, storage, and handling of Study Drug or Study Device will be in compliance
with all applicable laws and regulations, the Protocol, and CRO’s or Sponsor’s written instructions.

 

1.4.
CRO, Clinic, Principal Investigator, and Institution shall comply with and conduct all aspects of the Study in compliance with
all applicable federal, state, and local laws and regulations, including generally accepted standards of good clinical practice
as adopted by current FDA regulations and statutes and regulations of the U.S. Government relating to exportation of technical
data, computer software, laboratory prototypes, and other commodities as applicable to academic institutions. Institution and
Clinic will only allow individuals who are appropriately trained and qualified to assist in the conduct of the Study.

 

1.5.
Institution and/or Clinic shall obtain IRB approval for this Study and proof thereof shall be provided to CRO. Initiation of the
Protocol and Institution’s and Clinic’s obligations to conduct the Study shall not begin until IRB approval is obtained.
Institution and/or Clinic shall obtain from each subject, prior to the subject’s participation in the Study, a signed informed
consent and necessary authorization to disclose health information to CRO and/or Sponsor in a form approved in writing by the
IRB or a waiver of consent as directed by the IRB and further provided that the informed consent is consistent with Institution’s
and/or Clinic’s policies.

 

1.6.
Institution and/or Clinic shall promptly inform Sponsor of any urgent safety measures as instructed in the Protocol or breaches
of the Protocol of which Institution and/or Clinic becomes aware.

 

1.7.
Institution and Clinic acknowledge CRO’s right to assign or transfer, in whole, with notice to Institution and Clinic, any
of its rights or obligations under this Agreement to the Sponsor or Sponsor’s designate, provided however that CRO shall
remain liable for all of CRO’s obligations incurred up to the date of transfer.

 

2.
Payments

 

Sponsor
will provide financial support for the Study and will provide such funds to CRO who will pay Institution in accordance with the
budget attached as Exhibit B (“Budget”) on a prorated basis, according to the actual work completed and any
non-cancelable obligated expenses, for subjects who are enrolled into the Study. The Parties acknowledge that the Budget amounts
represent an equitable exchange for the conduct of the Study in light of the professional time and expenses required for the performance
of the Study.

 

    	2

    	 

    

 

In
addition to other necessary routing information detailed in Exhibit B, each payment shall clearly reference the Study Protocol
Number and PI name.

 

For
administrative convenience, various Study contact information may be attached hereto and incorporated by reference as Exhibit
C, entitled, “Administrative & Study Points of Contact.”

 

The
Institution’s tax identification number is: 35-2346161.

 

Institution
shall pay Clinic pursuant to Exhibit E. All payments from Institution to Clinic will be pass-through payments, and Institution
will not be liable for payment to Clinic until Institution has been paid in full by CRO.

 

3.
Confidentiality

 

3.1.
It is anticipated that in the performance of this Agreement, Sponsor and/or CRO on behalf of Sponsor may need to disclose to Institution
and/or Clinic information which is considered confidential. The rights and obligations of the Parties with respect to such information
are as follows:

 

“Confidential
Information” refers to information of any kind which is disclosed to the Institution and/or Clinic by Sponsor and/or CRO
on behalf of Sponsor for purposes of conducting the Study or Data (as defined below in Section 4) which:

 

	 	a)	by
    appropriate marking, is identified as confidential and proprietary at the time of disclosure;
	 	 	 
	 	b)	if
    disclosed orally, is identified in a marked writing within thirty (30) days as being confidential.

 

Sponsor
and/or CRO on behalf of Sponsor will make reasonable efforts to mark Confidential Information as stated in (a) and (b) above.
However, to the extent such marking is not practicable, then in the absence of written markings, information disclosed (written
or verbal) that a reasonable person familiar with the Study would consider it to be confidential or proprietary from the context
or circumstances of disclosure shall be deemed as such.

 

Notwithstanding
the foregoing, Data and results generated in the course of conducting the Study are not Confidential Information for publishing
purposes in accordance with Section 9 of this Agreement. Institution and Clinic agree, for a period of five (5) years following
the termination or expiration of this Agreement, to use reasonable efforts, no less than the protection given their own confidential
information, to use Confidential Information received from Sponsor and/or CRO on behalf of Sponsor in accordance with this Section.

 

Institution
and Clinic agree to use Sponsor’s Confidential Information solely as allowed by this Agreement, and for the purposes of
conducting the Study or administrative purposes. Institution and Clinic agree to make Sponsor’s Confidential Information
available only to those of its, or its affiliated hospitals’ employees, IRB members, personnel, agents, consultants, and
vendors, and approved subcontractors, as applicable, who require access to it in the performance of this Study or for administrative
purposes, and are subject to similar terms of confidentiality, including, without limitation, the Principal Investigator.

 

    	3

    	 

    

 

3.2.
The obligation of nondisclosure does not apply with respect to any of the Confidential Information that:

 

	 	a)	is
    or becomes public knowledge through no breach of this Agreement by Institution and/or Clinic;
	 	 	 
	 	b)	is
    disclosed to Institution and/or Clinic by a third party entitled to disclose such information without known obligation of
    confidentiality;
	 	 	 
	 	c)	is
    already known or is independently developed by Institution and/or Clinic without use of Sponsor’s Confidential Information
    as shown by Institution’s and/or Clinic’s contemporaneous written records;
	 	 	 
	 	d)	is
    necessary to obtain IRB approval of Study or required to be included in the written information summary provided to Study
    subject(s) and/or informed consent form;
	 	 	 
	 	e)	is
    released with the prior written consent of the Sponsor; or
	 	 	 
	 	f)	is
    required to support the medical care of a Study Subject.

 

3.3.
Institution and/or Clinic may disclose Confidential Information to the extent that it is required to be produced pursuant to a
requirement of applicable law, IRB, government agency, an order of a court of competent jurisdiction, or a facially valid administrative,
Congressional, or other subpoena, provided that Institution or Clinic, subject to the requirement, order, or subpoena, promptly
notifies Sponsor. To the extent allowed under applicable law, Sponsor may seek to limit the scope of such disclosure and/or seek
to obtain a protective order. Institution and/or Clinic will disclose only the minimum amount of Confidential Information necessary
to comply with law or court order as advised by Institution’s or Clinic’s legal counsel.

 

3.4.
No license or other right is created or granted hereby, except the specific right to conduct the Study as set forth by Protocol
and under terms of this Agreement, nor shall any license or other right with respect to the subject matter hereof be created or
granted except by the prior written agreement of the Parties duly signed by their authorized representatives.

 

3.5.
Upon Sponsor’s and/or CRO’s written request, Institution and Clinic agree to return all Confidential Information supplied
to it/them by Sponsor and/or CRO on behalf of Sponsor at Sponsor’s expense pursuant to this Agreement except that Institution
and Clinic may each retain such Confidential Information in a secure location for purposes of identifying and satisfying its obligations
and exercising its rights under this Agreement.

 

3.6
Institution and Clinic may disclose the existence of this Agreement and any additional information necessary to ensure compliance
with applicable Federal, State and Institutional and/or Clinic policies, regulations, and laws.

 

3.7
All information including, without limitation: (i) financial data, other data, reports, personnel information, know-how, or business
or research plans of Institution or Clinic that are provided to Sponsor and/or CRO in connection with this Agreement or the Study;
and (ii) Study subjects’ medical records and source documents created by Institution, Clinic, Principal Investigator, or
Study staff in connection with the Study (except for Study Data, results, or reports) is confidential information (“Institution/Clinic
Confidential Information”). Institution/Clinic Confidential Information and all tangible expressions, in any media, of Institution/Clinic
Confidential Information are and shall remain the sole property of Institution and/or Clinic. Sponsor and/or CRO shall not disclose
Institution/Clinic Confidential Information except: (1) as expressly permitted by this Agreement; (2) to its own personnel who
reasonably require access to such Institution/Clinic Confidential Information and are subject to an obligation to maintain the
confidentiality of the Institution/Clinic Confidential Information; (3) to the extent such information was known by Sponsor and/or
CRO or the public prior to the receipt of information; (4) to the extent such information is provided by a third party and Sponsor
and/or CRO has no reason to believe the information was wrongfully obtained by the third party; (5) to the extent such disclosure
is required by law; (6) at the time of its receipt the Institution/Clinic Confidential Information is, or later becomes, available
to the public through no fault of the Sponsor or CRO; or (7) is independently developed by the Sponsor and/or CRO without reference
to Institution/Clinic Confidential Information.

 

    	4

    	 

    

 

4.
Data Use/Ownership

 

“Data”
shall mean all data and information generated by Institution and/or Clinic as a result of conducting the Study in accordance with
the IRB approved Protocol. Data does not include original Study subject or patient medical records, research notebooks, source
documents, or other routine internal documents kept in the Institution’s and/or Clinic’s ordinary course of business
operations, which shall remain the sole and exclusive property of the Institution, Clinic, or medical provider. Sponsor owns and
has the right to use the Data in accordance with the signed informed consent and authorization form, applicable laws, and the
terms of this Agreement. Notwithstanding any licenses or other rights granted to Sponsor herein, but in accordance with the confidentiality
and publication sections herein, Institution and Clinic shall retain the right to use the Data and results for its publication,
IRB, regulatory, legal, clinical, educational, and internal research purposes.

 

5.
HIPAA/HIPAA Privacy

 

5.1.
Institution and Clinic shall comply with applicable laws and regulations, as amended from time to time, including without limitation,
the Health Insurance Portability and Accountability Act of 1996 and its implementing regulations (HIPAA) with respect to the collection,
use, storage, and disclosure of Protected Health Information (PHI) as defined in HIPAA. CRO and Sponsor, through Its agreement
with CRO, shall collect, use, store, access, and disclose PHI collected from Study subjects only as permitted by applicable laws
and regulations and the IRB approved informed consent form or HIPAA authorization form obtained from a Study subject. Sponsor
will collect, use, store, and disclose any Subject Material, defined in Section 15, it receives only in accordance with the informed
consent form and, in any event, will not collect, use, store, or disclose any PHI attached to or contained within the Subject
Material in any manner that would violate this Section of the Agreement.

 

Institution
and Clinic acknowledge that, pursuant to Section 111 of the Medicare, Medicaid, and SCHIP Extension Act of 2007 (“MMSEA”),
Sponsor has an obligation to submit certain reports to the Centers for Medicare & Medicaid Services with respect to Medicare
beneficiaries who participate in the Study and experience a research injury for which diagnosis or treatment costs are incurred.
Sponsor and CRO recognize that each party is subject to laws and regulations protecting the confidentiality of research subject
information. Accordingly: (1) Institution and/or Clinic agree upon prior written request to provide to Sponsor, or CRO as designated
by Sponsor, certain identifiable patient information required by MMSEA for Study subjects who are Medicare beneficiaries and incur
medical costs in association with a research injury and whose costs are reimbursed by Sponsor pursuant to this Agreement; and
(2) Institution and Clinic further agree to otherwise cooperate with Sponsor (and CRO as designated by Sponsor) to the extent
necessary for Sponsor to meet its MMSEA reporting obligations.

 

    	5

    	 

    

 

5.2.
CRO’s ability to review the Study subjects’ Study-related information contained in the Study subject’s medical
record shall be subject to reasonable safeguards for the protection of Study subject confidentiality and the Study subjects’
informed consent form or HIPAA authorization form.

 

5.3.
Neither CRO, nor Sponsor through its agreement with CRO, shall attempt to identify, or contact, any Study subject unless permitted
by the informed consent form.

 

5.4
In the event that CRO, or Sponsor through its agreement with CRO, receives or observes information about patients who are not
participating in the Study, CRO and Sponsor will maintain the confidentiality of, and will not disclose to any third party, such
information, including the patient’s identity in accordance with state and federal laws regarding the confidentiality of
such records.

 

6.
Record Retention

 

As
applicable by law, Institution and/or Clinic shall retain and preserve a copy of the Study records for the longer of:

 

	 	a)	two
    (2) years after a marketing authorization for Study Drug, or Study Device has been approved for the indication for which it
    was investigated or Sponsor has discontinued research on the Study Drug or Study Device;
	 	 	 
	 	b)	such
    longer period as required by federal regulatory requirements; or
	 	 	 
	 	c)	as
    requested by Sponsor at Sponsor’s reasonable storage expense.

 

CRO
will provide written notification to Institution and Clinic if Sponsor performs actions which would extend the period of time
records are required to be maintained under applicable law beyond ten (10) years following the termination or expiration of this
Agreement so that Institution and Clinic may comply with its document retention obligations stated herein. After the retention
period, Institution and/or Clinic may contact CRO or Sponsor to discuss disposition of records; unless Sponsor requests additional
retention time, at Sponsor’s reasonable expense, within 30 days of such notice, Institution and Clinic shall be free to
move forward with destruction of Study records without further inquiry to Sponsor.

 

7.
Monitoring and Auditing

 

7.1.
Site visits by Sponsor, CRO and/or another authorized designee (e.g., Study monitor) will be scheduled in advance for times mutually
acceptable to the Parties during normal business hours. Sponsor’s, CRO’s and/or authorized designee’s access
is subject to reasonable safeguards to ensure confidentiality of medical records and systems.

 

7.2.
Upon becoming aware of an audit or investigation by a regulatory agency with regard to the Study, Institution and/or Clinic agree
to provide Sponsor with prompt notice of the auditor investigation. If legally permissible or allowable by the regulatory agency
and permissible in accordance with the Institution’s and/or Clinic’s policy, Sponsor may be available or request to
be present with approval from auditor during such audit, but Sponsor will not alter or interfere with any documentation or practice
of Institution or Clinic. Institution and/or Clinic shall be free to respond to any regulatory agency inquiries and will provide
Sponsor with a copy of any formal response or documentation to the regulatory agency regarding the Study,

 

    	6

    	 

    

 

8.
Inventions, Discoveries and Patents

 

8.1.
It is recognized and understood that certain existing inventions and technologies, and those arising outside of the research conducted
under this Agreement, are the separate property of Sponsor, Clinic, or Institution and are not affected by this Agreement, and
neither Sponsor, Clinic, nor Institution shall have any claims to or rights in such separate inventions and technologies.

 

8.2.
Any new patentable inventions, developments, or discoveries made during and in the performance of the Study (“Inventions”)
shall be promptly disclosed to Sponsor. Title to Inventions that necessarily use or necessarily incorporate Sponsor’s Study
Drug and/or Study Device shall reside with Sponsor (“Sponsor Inventions”). Institution, Clinic, and Principal Investigator
shall assign all Sponsor Inventions to Sponsor in writing. Title to Inventions other than Sponsor Inventions (“Other Inventions”)
shall reside with Sponsor if Sponsor personnel are the sole inventors, with Institution If Institution and Clinic personnel are
the sole inventors, and shall be held jointly if both Institution and/or Clinic and Sponsor personnel are inventors. Institution’s,
Clinic’s, and/or Principal Investigator’s obligations under Sections 8.2 and 8.3 hereunder shall be performed by its/their
appropriate office(s) with technology transfer responsibilities, if required by and in accordance with Institution’s and/or
Clinic’s policies.

 

8.3.
To the extent that Institution and/or Clinic owns sole or joint title in any such Other Inventions, Sponsor is hereby granted,
without option fee other than consideration of the Study sponsored herein and the reimbursement to Institution and/or Clinic for
patent expenses incurred prior to or during the option period, an option to acquire an exclusive, worldwide, royalty-bearing license
to Institution’s and Clinic’s rights to any Other Invention, which option shall extend for no more than ninety (90)
days after Sponsor’s receipt of an Invention disclosure from Institution and/or Clinic (“Option Period”). Sponsor
and Institution and/or Clinic shall use their reasonable efforts to negotiate, for a period not to exceed ninety (90) days after
Sponsor’s exercise of such option, a license agreement satisfactory to all parties (“Negotiation Period”). In
the event Sponsor fails to exercise its option within the Option Period, or Sponsor and Institution and/or Clinic fail to reach
agreement on the terms of such license within the Negotiation Period, Institution and/or Clinic shall have no further obligation
to Sponsor under this Agreement with regard to the specific Other Invention.

 

8.4.
Institution and Clinic shall retain a royalty-free, irrevocable license to use for its own internal noncommercial research, educational
and patient care purposes, all Sponsor Inventions or Other Inventions licensed or assigned to Sponsor hereunder.

 

8.5.
Nothing contained in this Agreement shall be deemed to grant either directly by implication, estoppel, or otherwise any license
under any patents, patent applications, or other proprietary interest to any other inventions, discovery or improvement of either
Sponsor, Institution, or Clinic.

 

8.6.
CRO, Clinic, and Institution agree that the provisions of this Agreement are intended to be interpreted and implemented so as
to comply with all applicable federal laws, rules, and regulations, including without limitation the requirements of Rev. Proc.
2007-47; provided, however, if it is determined by the Internal Revenue Service or any other federal agency or instrumentality
(the “Government”) that the provisions of this Agreement are not in such compliance, then those parties agree to modify
the provisions and the implementation of this Agreement so as to be in compliance with all applicable federal laws, rules, and
regulations as determined by the Government.

 

    	7

    	 

    

 

9.
Publication

 

9.1.
Institution and Clinic shall be free to publish, present, or use any Data and results arising out of its performance of the Protocol
(individually, a “Publication”). At least thirty (30) days prior to submission for Publication, Institution and/or
Clinic shall submit to Sponsor for review and comment any proposed oral or written Publication (“Review Period”).
Institution and/or Clinic will consider any such comments in good faith but is under no obligation to incorporate Sponsor’s
suggestions. The Review Period for abstracts or poster presentations shall be thirty (30) days. If during the Review Period, Sponsor
notifies Institution and/or Clinic in writing that: (i) it desires patent applications to be filed on any inventions disclosed
or contained in the disclosures, Institution and/or Clinic will defer Publication for a period not to exceed sixty (60) days,
to permit Sponsor to file any desired patent applications; and (ii) if the Publication contains Sponsor’s Confidential Information
as defined in Section 3 and Sponsor requests Institution and/or Clinic in writing to delete such Sponsor’s Confidential
Information, the Institution and/or Clinic agrees to delete such Sponsor’s Confidential Information only to the extent such
deletion does not preclude the complete and accurate presentation and interpretation of the Study results.

 

9.2.
The Parties agree that this Study is a multi-center clinical trial. Therefore, Institution and Clinic agree that the first Publication
of the results of the Study shall be made in conjunction with the presentation of a joint multi-center Publication of the Study
results with the Principal Investigators from all sites contributing Data, analyses, and comments. However, Institution and Clinic
may publish the Data and Study results individually in accordance with this Section 9 upon first occurrence of one of the following:
(i) multi-center Publication is published; (ii) no multi-center publication is submitted within eighteen (18) months after conclusion,
abandonment, or termination of the Study at all sites; or (iii) Sponsor confirms in writing there will be no multi-center Publication.

 

9.3.
If no multi-center Publication occurs within eighteen (18) months of the completion of the Study at all sites, upon request by
Institution and/or Clinic, Sponsor will provide such Institution and Clinic access to the aggregate Data from all Study sites.

 

9.4.
If the Institution and Clinic, through its Principal Investigator, is identified to participate in the multi-center Publication:
(i) Institution and Clinic will have the opportunity to review the aggregate multi-center Data, upon request; and (ii) consistent
with the International Committee of Medical Journal Editors (ICMJE) regulations, Institution and Clinic will have adequate opportunity
to review and provide input on any abstract or manuscript prior to its submission for Publication. Institution and Clinic also
retains the right, on behalf of its Principal Investigator, to decline to be an author on any Publication.

 

10.
Use of Name

 

10.1.
Neither Institution, Clinic, nor CRO may use the name, trademark, logo, symbol, or other image or trade name of the other Parties
or their employees and agents in any advertisement, promotion, or other form of publicity or news release or that in any way implies
endorsement without the prior written consent of an authorized representative of the other Party whose name is being used. Such
approval will not be unreasonably withheld.

 

10.2.
Institution and Sponsor understand that the amount of any payment made hereunder may be disclosed and made public by the other
party as required by law or regulation, including the Patient Protection and Affordable Care Act of 2010, provided that the disclosure
clearly designates the payment as having been made to Institution for research and not to the physician.

 

    	8

    	 

    

 

10.3.
Institution, Clinic, and Principal Investigator may acknowledge the Sponsor’s support, including but not limited to financial
support as may be required by academic journals, professional societies, funding agencies, and applicable regulations. Notwithstanding
anything to the contrary in this Agreement, Institution may publicly post information about the Study on Institution’s clinical
trials directory/website. Additionally, notwithstanding anything herein to the contrary, Institution shall have the right to post
Sponsor’s and/or CRO’s names, the Study title, and the Study period, and funding amount, on Institution publicly accessible
lists of research conducted by the Institution.

 

11.
Indemnification and Limitation of Liability

 

11.1
Sponsor’s indemnification obligations are outlined in a separate Letter of Indemnification, attached hereto as Exhibit
D.

 

11.2.
CRO expressly disclaims any liability in connection with the Study Drug or Study Device, including any liability for any claim
arising out of a condition caused by or allegedly caused by any Study procedures associated with such product except to the extent
that such liability is caused by the negligence, willful misconduct, or breach of this Agreement by CRO.

 

11.3
CRO shall defend, indemnify and hold harmless Institution, Clinic, and Principal Investigator and their respective trustees, employees,
agents, contractors, and/or consultants from and against any claims, loss, liability, damage, cost and expense of claims (including
reasonable attorney’s fees) and suits (together “Claims”), alleged to be caused by or arising from CRO’s
negligence, willful misconduct, or breach of this Agreement.

 

11.4
Institution and Clinic shall defend, indemnify and hold harmless CRO and their respective trustees, employees, agents, contractors,
and/or consultants from and against any claims, loss, liability, damage, cost and expense of claims (including reasonable attorney’s
fees) and suits (together “Claims”), alleged to be caused by or arising from Institution’s, Clinic’s,
and/or Principal Investigator’s negligence, willful misconduct, or breach of this Agreement.

 

12.
Subject Injury

 

Sponsor’s
subject injury obligations are outlined in Exhibit D.

 

13.
Insurance

 

13.1.
Institution shall, at its sole cost and expense maintain a policy or program of insurance or self- insurance at the level of at
least $1,000,000 per occurrence (or per claim) and $3,000,000 annual aggregate to support its obligations assumed in this Agreement.
However, if Institution is a public entity entitled to governmental immunity protections under applicable state law, then Institution
may provide liability coverage in accordance with any limitations associated with the applicable law.

 

Clinic
shall, at its sole cost and expense maintain a policy or program of insurance or self- insurance at the level of at least $1,000,000
per occurrence (or per claim) and $3,000,000 annual aggregate to support its obligations assumed in this Agreement, However, if
Clinic is a public entity entitled to governmental immunity protections under applicable state law, then Clinic may provide liability
coverage in accordance with any limitations associated with the applicable law.

 

13.2.
CRO shall maintain an insurance policy or a program of self-insurance at levels sufficient to support its obligations assumed
herein.

 

    	9

    	 

    

 

13.3.
Upon written request, either Party will provide evidence of its insurance or self-insurance acceptable to the other Party. A Party’s
inability to meet its insurance obligation constitutes material breach of this Agreement.

 

14.
Term and Termination

 

14.1.
The term of this Agreement shall commence upon the Effective Date and terminate upon the completion of the Parties’ Study-related
activities under the Agreement, unless terminated early as further described in this Section.

 

14.2.
CRO has the right to terminate this Agreement upon thirty (30) days prior written notice to the Institution and Clinic. This Agreement
may be terminated immediately at any time for any reason by the Institution or CRO when, in their judgment or that of the Principal
Investigator, the Institution’s IRB, Scientific Review Committee, if applicable, or the Food and Drug Administration, it
is determined to be inappropriate, impractical, or inadvisable to continue, in order to protect the Study subjects’ rights,
welfare, and safety, or the IRB otherwise disapproves the Study. If for any reason Principal Investigator becomes unavailable
to direct the performance of the work under this Agreement, Institution and/or Clinic shall promptly notify CRO. If the Parties
are unable to identify a mutually acceptable successor, this Agreement may be terminated by either Party upon thirty (30) days
written notice.

 

14.3.
Notwithstanding the above a Party may, in addition to any other available remedies:

 

	 	a)	immediately
    terminate this Agreement upon the other Party’s material failure to adhere to the Protocol, except for deviation required
    to protect the rights, safety, and welfare of Study subjects; and/or
	 	 	 
	 	b)	terminate
    this Agreement upon the other Party’s material default or breach of this Agreement, provided that the defaulting/breaching
    Party fails to remedy such material default, breach, or failure to adhere to the Protocol within thirty (30) business days
    after written notice thereof.

 

14.4.
In addition to the above:

 

	 	a)	This
    Agreement may be terminated by Institution in the event of a material default or breach of this Agreement by CRO, or by CRO
    in the event of a material breach of this Agreement by Institution, provided that the defaulting/breaching party fails to
    remedy such material default or breach within thirty (30) business days after written notice thereof.
	 	 	 
	 	b)	A
    Party may terminate this Agreement upon ninety (90) days’ written notice for any reason.

 

14.5.
In the event that this Agreement is terminated prior to completion of the Study, for any reason, Institution and/or Clinic shall:

 

	 	a)	notify
    the IRB that the Study has been terminated;
	 	 	 
	 	b)	cease
    enrolling subjects in the Study;

 

    	10

    	 

    

 

	 	c)	cease
    treating Study subjects under the Protocol as directed by CRO to the extent medically permissible and appropriate;
	 	 	 
	 	d)	terminate,
    as soon as practicable, all other Study activities; and
	 	 	 
	 	e) 	furnish
    to CRO any required final report for the Study in the form reasonably acceptable to CRO.

 

Promptly
following any such termination, Institution and Clinic will provide to CRO copies of Data collected pursuant to the Study Protocol.
Upon Sponsor’s or CRO’s written request, Institution and Clinic shall provide to the requesting party, at Sponsor’s
or CRO’s expense, all Sponsor’s Confidential Information provided under this Agreement provided, however, that Institution
and Clinic may retain such copy of Confidential Information for record keeping purposes, monitoring its obligations, and exercising
its rights hereunder, subject to Institution’s and/or Clinic’s ongoing compliance with the confidentiality and non-use
obligations set forth in this Agreement.

 

14.6.
If this Study is terminated early, the Institution shall be reimbursed for all work completed, on a pro rata basis, and reasonable
costs of bringing the Study to termination incurred through the date of termination, and for non-cancelable commitments properly
incurred through that date. Upon receipt of notice of termination, Institution and Clinic will use reasonable efforts to reduce
or eliminate further costs and expenses and will cooperate with CRO to provide for an orderly wind- down of the Study.

 

14.7.
Subsections 1.4,1.6, and 14.6, and Sections 2, 3,4, 5, 6, 7,8,9,10,11 (and the attached Letter of Indemnification), 12,13,15,19
and 23, shall survive any termination or expiration of this Agreement, except that Section 3 shall survive for the period stated
in Section 3.1. Any provision of this Agreement that by its nature and intent remains valid after termination will survive termination.

 

15.
Subject Material

 

15.1.
Subject Material means any biologic material of human origin including, without limitation, tissues, blood, plasma, urine, spinal
fluid, or other fluids derived from the Study subjects in accordance with and pursuant to the Protocol (“Subject Material”).

 

15.2.
Institution and Clinic agree to make the Subject Material available to the Sponsor in accordance with the Protocol for the purposes
of the Study. The Subject Material may be used by the Sponsor, central lab, or other contracted party only as allowed by the Study
subject’s informed consent form or pertinent institutional review board(s). Sponsor’s use of Subject Materials, other
than as allowed by the Study subject’s informed consent form, will require additional IRB review and approval.

 

16.
Subcontract

 

If
applicable, Institution and Clinic have the right to subcontract to other sites to conduct the Study in accordance with the Protocol
with terms consistent with this Agreement with written approval of the Sponsor, which approval shall not be unreasonably withheld.
If Institution and/or Clinic subcontracts any Study related duties, Institution and/or Clinic shall contract with such subcontractors
incorporating terms substantially similar to the terms herein. Such subcontracts may be provided to the CRO upon written request.

 

    	11

    	 

    

 

The
Parties acknowledge and agree that the Sponsor and each of its affiliates is a third-party beneficiary to this Agreement.

 

17.
Notices

 

Any
notice, authorization, approval, consent or other communication will be in writing and deemed given:

 

	 	a)	Upon
    delivery in person;
	 	b)	Upon
    delivery by courier;
	 	c)	Upon
    delivery date by a nationally-recognized overnight delivery service such as FedEx.

 

If
to CRO:

Cancer
Insight, LLC

Attn:
Steven White

Chief
Operating Officer

110
E. Houston St.

San
Antonio, TX 78205

210-884-0810

swhite@cancerinsight.com

 

If
to Sponsor:

BriaCell
Therapeutics Corp.

820
Heinz Avenue

Berkeley,
CA 94710

Tel:
1-888-485-6340

Fax:
424-245-3719

 

If
to Institution:

Providence
Regional Medical Center Everett

Attn:
Marilyn Birchman, MSN, RN, AOCNS

1330
Rockefeller Avenue, Suite 440

Everett,
Washington 98201

 

If
to Clinic:

The
Everett Clinic PLLC

Attention:
Chief Medical Officer

3901
Hoyt Avenue

Everett,
WA 98201

 

With
a copy to Principal Investigator:

Jason
Lukas, MD

Providence
Regional Medical Center Everett

1717
13th Street Suite 300

Everett,
Washington 98201

 

18.
Independent Contractor

 

It
is mutually understood and agreed that the relationship between Institution, Clinic, and CRO is that of independent contractors.
Neither Institution, Clinic, nor CRO party shall represent itself as the agent, employee, partner, joint venturer, or servant
of the other. Except as specifically set forth herein, neither Institution, Clinic, nor CRO shall have nor exercise any control
or direction over the methods by which the others perform work or obligations under this Agreement. Further, nothing in this Agreement
is intended to create any partnership, joint ventures, lease, or equity relationship, expressly or by implication, among those
parties.

 

    	12

    	 

    

 

19.
Clinical Trial Registry

 

Prior
to enrollment of the first subject in the Study, Sponsor will register the Study on www.clinicaltrials.gov in accordance with
the requirements of the International Committee of Medical Journal Editors (ICMJE) and Public Law 110-85. Results of this Study
will be reported in compliance with applicable laws.

 

20.
Non-Referral/Anti-Corruption Language

 

20.1.
Institution, Clinic, and CRO, on behalf of Sponsor, agree that it is not their intent under this Agreement to induce or encourage
the unlawful referral of subjects or business between the Parties, and there shall not be any requirement under this Agreement
that those parties, their employees or affiliates, including their medical staff, engage in any unlawful referral of subjects
to, or order or purchase products or services from, one of those parties.

 

20.2.
Institution, Clinic, and CRO, on behalf of Sponsor, agree that their employees, who are involved in the conduct of the Study,
will not offer, pay, request or accept any bribe, inducement, kickback or facilitation payment, and shall not make or cause another
to make any offer or payment to any individual or entity for the purpose of influencing a decision for the benefit of one of those
parties.

 

21.
Force Majeure

 

If
any Party hereto shall be delayed or hindered in, or prevented from, the performance of any act required hereunder for any reason
beyond such Party’s direct control, including but not limited to, strike, lockouts, labor troubles, governmental or judicial
actions or orders, riots, insurrections, war, acts of God, inclement weather, or other reason beyond the Party’s control
(a “Disability”) then such Party’s performance shall be excused for the period of the Disability. Any Study
timelines affected by a Disability shall be extended for a period equal to the delay and any affected Budget shall be adjusted
to account for cost increases or decreases resulting from the Disability. The Party affected by the Disability shall notify the
other Party of such Disability as provided for herein.

 

22.
Counterparts

 

This
Agreement may be executed in any number of counterparts, each of which shall be an original and all of which together shall constitute
one and the same document, and is binding on all Parties notwithstanding that each of the Parties may have signed different counterparts.
Facsimiles or scanned copies of signatures or electronic images of signatures shall be considered original signature unless prohibited
by applicable law.

 

    	13

    	 

    

 

23.
Debarment

 

The
Institution and Clinic certifies that to its knowledge neither it, nor any of its employees, agents or other persons performing
the Study under its direction, is currently debarred, suspended, or excluded under the Federal Food, Drug and Cosmetic Act, as
amended, or disqualified under the provisions of 21 CFR §312,70. In the event that the Principal Investigator or any Study
personnel becomes debarred or disqualified during the term of this Agreement or within 1 year after termination of the Study,
the Institution and/or Clinic agrees to promptly notify CRO after learning of such event, institution and Clinic certifies that
it is not excluded from a federal health care program, including Medicare and Medicaid. In the event Institution and/or Clinic
becomes excluded during the term of this Agreement or within 1 year after termination of the Study, the Institution and/or Clinic
agrees to promptly notify CRO after learning of such event.

 

24.
Choice of Law -Intentionally omitted

 

25. Entire Agreement

 

Section
and clause headings are used herein solely for convenience of reference and are not intended as substantive parts of the Parties’
agreement. This ACTA incorporates the Exhibits referenced herein. This written ACTA constitutes the entire agreement between the
Parties concerning the subject matter, with exception of the Research Collaboration and Services Agreement between Institution
and Clinic, and supersedes all other or prior agreements or understandings, whether written or oral, with respect to that subject
matter. Any changes made to the terms, conditions or amounts cited in this ACTA require the written approval of each Party’s
authorized representative.

 

The
authorized representatives of the Parties have signed this ACTA as set Forth below.

 

	Providence Health & Services - Washington, dba	 	Cancer Insight, LLC
	Providence Regional medical Center Everett	 	 	 
	 	 	 	 	 
	By:		 	By:	
	Name:	Scott Combs	 	Name:	Steven White
	Title:	Chief Financial Officer	 	Title:	Chief Operating Officer
	Date:	9/27/2018	 	Date:	September 27, 2018

 

	The Everett Clinic, PLLC	 	Principal Investigator
	By:		 	By:	
	Name:	Albert W. Fisk, MD	 	Name:	Jason Lukas, MD
	Title:	Chief Medical Officer

The Everett Clinic	 	Title:	
	Date:	9/29/18	 	Date:	9/13/18

 

    	14

    	 

    

 

EXHIBIT
A

PROTOCOL

 

See
attached and incorporated master Protocol, which is identified as Protocol BRI-ROL-001 and consent form.

 

    	15

    	 

    

 

EXHIBIT
B

BUDGET

 

	A.	This
    Budget has been negotiated at fair and reasonable value. Institution has not been influenced to participate in this Study
    based on financial or other inducements from Sponsor. The compensation may be used at the discretion of Institution to offset
    the costs of the Study. For Study subject visit and Study conduct reimbursements, an item listed herein will be considered
    payable upon Institution’s complete and accurate data entry into the applicable electronic data capture system (EDC)
    of all assessments associated with that visit in the EDC.
	 	 
	B.	Sponsor
    will not be liable for any payment in excess of the fees and costs provided herein except upon Sponsor’s prior written
    agreement. Institution may submit to Sponsor a revised budget requesting additional funds at such time as expenses may reasonably
    be projected to exceed the fees and costs provided herein.
	 	 
	C.	The
    compensation per Study subject will be earned by Institution and made payable by Sponsor as follows:

 

	 	i.	$1,500.00
    will be paid upon completion of the baseline visit, as defined by the Protocol; it $1,500.00 will be paid upon completion
    of Cycle One, as defined by the Protocol;
	 	 	 
	 	iii.	$1,500.00
    will be paid upon completion of Cycle Two, as defined by the Protocol;
	 	 	 
	 	iv.	$1,500.00
    will be paid upon completion of Cycle Three, as defined by the Protocol;
	 	 	 
	 	v.	$1,500.00
    will be paid upon completion of Cycle Four, as defined by the Protocol;
	 	 	 
	 	vi.	$1,500.00
    will be paid upon completion of Cycle Five, as defined by the Protocol;
	 	 	 
	 	vii.	$1,500.00
    will be paid upon completion of Cycle Six, as defined by the Protocol;
	 	 	 
	 	viii.	$1,500.00
    will be paid upon completion of Cycle Seven, as defined by the Protocol;
	 	 	 
	 	ix.	$1,500.00
    will be paid upon completion of Cycle Eight, as defined by the Protocol;
	 	 	 
	 	x.	$1,500.00
    will be paid upon completion of Cycle Nine, as defined by the Protocol;
	 	 	 
	 	xi.	$1,500.00
    will be paid upon completion of Cycle Ten, as defined by the Protocol;
	 	 	 
	 	xii.	$1,500.00
    will be paid upon completion of Cycle Eleven, as defined by the Protocol;
	 	 	 
	 	xiii.	$1,500.00
    will be paid upon completion of Cycle Twelve, as defined by the Protocol;

 

    	16

    	 

    

 

	 	xiv.	$1,500.00
    will be paid upon completion of Cycle Thirteen, as defined by the Protocol;
	 	 	 
	 	xv.	$1,500.00
    will be paid upon completion of Cycle Fourteen, as defined by the Protocol;
	 	 	 
	 	xvi.	$1,500.00
    will be paid upon completion of Cycle Fifteen, as defined by the Protocol;
	 	 	 
	 	xvii.	$1,500.00
    will be paid upon completion of Cycle Sixteen, as defined by the Protocol;
	 	 	 
	 	xviii.	$1,500.00
    will be paid upon completion of Cycle Seventeen, as defined by the Protocol;
	 	 	 
	 	xix.
    	$1,500.00
    will be paid upon completion of the final assessment follow-up visit, as defined by the Protocol.

 

	D.	Start-up
    funding will be provided in the amount of $10,000.00 and payable upon execution of the Agreement, which may be used at the
    discretion of Institution to offset the costs of the Study.
	 	 
	E.	Where
    Institution utilizes Western IRB (“WIRB”) as their central IRB, Cancer Insight will pay for WIRB costs directly
    and Institution may direct WIRB to invoice Cancer Insight directly. Where Institution utilizes a local IRB, CRO will reimburse
    Institution for fees charged by the local IRB related to the Study, including but not limited to fees for initial and continuing
    reviews, amendments to the Protocol, consent form and advertisements proposed after initial review, and changes to the consent
    form.
	 	 
	F.	The
    following administrative fees shall be invoiceable to Sponsor:

 

	 	i.	An
    annual pharmacy administrative fee shall be provided in the amount of $960.00 per year:
	 	 	 
	 	ii.	A
    monitor change fee in the amount of $500.00 per occurrence;
	 	 	 
	 	iii.	A
    protocol amendment fee in the amount of $500.00 per occurrence;
	 	 	 
	 	iv.	An
    SAE fee in the amount of $200.00 per occurrence;
	 	 	 
	 	v.	A
    one-time document storage and archiving fee in the amount of $1,000.00;
	 	 	 
	 	vi.	A
    one-time study close-out fee in the amount of $750.00;
	 	 	 
	 	vii.	A
    not-for-cause audit fee in the amount of $750.00 per occurrence;
	 	 	 
	 	viii.	An
    IND safety report fee in the amount of $35.00 per occurrence;
	 	 	 
	 	ix.	A
    re-consent fee in the amount of $45.00 per occurrence.

 

	G.	The
    cost of bone scan(s) shall be passed through to Sponsor. The cost of which is $962.00 per occurrence.

 

    	17

    	 

    

 

	H.	The
    cost of ECHO shall be passed through to Sponsor. The cost of which is $1,969.91 per occurrence.
	 	 
	I.	The
    cost of MUGA shall be passed through to Sponsor. The cost of which is $1,160.28 per occurrence.
	 	 
	J.	The
    cost of 12-Lead ECG shall be passed through to Sponsor. The cost of which is $220.00 per occurrence.
	 	 
	K.	Sponsor
    shall provide an annual allowance for screen failures (defined herein as patients who consent and qualify for the Study but,
    through no fault of Institution, withdraw from participation prior to their randomization to the Study) of $500.00 per patient
    for up to an annual total of ten (10) patients. Such reimbursement shall be invoiceable to Sponsor by Institution per occurrence.
    Any balance of this annual allowance shall not carry over to any subsequent years. This compensation may be used at the discretion
    of the Institution to offset the costs of the Study.
	 	 
	L.	Sponsor
    will provide pembrolizumab (KEYTRUDA®, anti-PD-1) and ipilimumab (YERVOY®, anti-CTLA-4), as applicable. Ipilimumab
    treatment is limited to four doses. For pembrolizumab, dosing may continue until disease progression, unacceptable toxicity,
    and/or up to twenty-four (24) months in Study subjects without disease progression.
	 	 
	M.	Sponsor
    will provide Interferon-Alpha, BriaVax, DTH (BriaTest), Anergy tests (Candin), and cyclophosphamide Study drugs.
	 	 
	N.	In
    the event any Protocol-required study drugs are provided by Institution through their pharmacy or other means, the cost of
    such shall be invoiceable by Institution and paid by Sponsor.
	 	 
	O.	Invoicing
    shall be conducted no more frequently than monthly. Invoices should be sent to Cancer Insight via email to Steven White at
    swhite@cancerinsight.com. In the event that such method of delivery is rendered impossible or impractical, invoices may be
    sent to Cancer Insight via mail to:

 

Cancer
Insight, LLC

Attn: Steven R. White

1422 E Grayson, 3rd Floor

San Antonio, TX 78208

 

	P.	Payments
    will be sent no later than thirty (30) days from receipt and approval of invoices. Payments will be issued via paper check
    to the following:

 

Providence
Health & Services - Washington d/b/a Providence Regional Medical Center Everett

Attn:
Marilyn Birchman, MSN, RN, AOCNS

1330
Rockefeller Avenue, Suite 440

Everett,
Washington 98201

 

With
each payment, Sponsor and/or CRO will identify the invoice, procedure or case report forms for which it is paid or provide other
means to ensure that the payment is properly attributed to the correct portion of the Study.

 

    	18

    	 

    

 

EXHIBIT
C

ADMINISTRATIVE
AND STUDY POINTS OF CONTACT

 

CRO
Clinical Department Point of Contact:

 

Karen
Arrington

karrington@cancerinsight.com

 

CRO
Regulatory Department Point of Contact:

 

Susie
Hargrove

shargrove@cancerinsight.com

 

CRO
Administrative and Billing Department Point of Contact:

 

Steven
White

swhite@cancerinsight.com

 

    	19

    	 

    

 

EXHIBIT
D

LETTER
OF INDEMNIFICATION (LOI)/SUBJECT INJURY

 

INSTITUTION:
Providence Health & Services - Washington, dba Providence Regional Medical Center Everett (the “Institution”)
and The Everett Clinic, PLLC (“Clinic”)

 

TITLE
OF CLINICAL TRIAL: “A Phase l/lla Rollover Study of the Whole-Cell Vaccine BriaVaxTM in Metastatic or Locally Recurrent
Breast Cancer Patients in Combination with Ipilinutmab or Pembrolizumab”

 

CRO:
Cancer Insight, LLC

 

STUDY
NUMBER: BRI-ROL-001

 

	1)	Institution,
    Principal Investigator, and Clinic have entered into the Agreement with CRO to participate in the above sponsored Study. CRO
    has been engaged by BriaCell Therapeutics Corp, (the “Sponsor”) to arrange and administer this BriaCell Therapeutics
    Corp, sponsored multi-center clinical trial.
	 	 
	2)	Sponsor
    has delegated to CRO responsibility for the management and monitoring of this Study. Sponsor has further authorized CRO to
    bind Sponsor to its obligations within the Agreement for this Study executed between CRO, Clinic, Principal Investigator,
    and Institution. Sponsor accepts responsibility for its obligations contained in the Agreement.
	 	 
	3)	Institution
    and Clinic agree to participate by allowing the Study to be undertaken utilizing such facilities, personnel and equipment
    as Institution and/or Clinic may reasonably need for its conduct of the Study. Institution and Clinic have entered into a
    separate Research Collaboration and Services Agreement The Study will be conducted by the Institution and Clinic under the
    direction of an employee of the Clinic.
	 	 
	4)	In
    consideration of such participation by Institution, Principal Investigator, and Clinic and subject to paragraph 5 below, the
    Sponsor shall defend, indemnify, and hold harmless the Institution, Clinic, and their respective medical affiliates and affiliated
    hospitals, and each of their contractors, trustees, officers, directors, governing bodies, subsidiaries, affiliates, investigators,
    employees, IRB members, agents, successors, heirs and assigns, including, without limitation the Principal Investigator (collectively
    referred to as “Institution’s Indemnitees”), from and against any third party claims, loss, liability, damage,
    cost and expense of claims (including reasonable attorney’s fees) and suits (“Claims”), alleged to be caused
    by or arising from: (1) the conduct of the Study; (2) use of the Study Drug or Study Device under this Agreement; (3) from
    the use of the Study results, or patient health information, regardless of the legal theory asserted; (4) any Sponsor Indemnitee’s
    (as that term is hereinafter defined) negligence or misconduct; or (5) any Sponsor Indemnitee’s breach of the Agreement
    or any applicable law or regulation.
	 	 
	5)	Sponsor
    shall have no obligation to provide such indemnification to the extent that such Claim is solely caused by Institution’s
    Indemnitee(s)’: (1) failure to adhere to and comply with all material and substantive specifications and directions
    set forth in the Protocol (except to the extent such deviation is reasonable to protect the rights, safety and welfare of
    the Study subjects); (2) failure to comply with all applicable laws and regulations in the performance of the Study; or (3)
    if such claim is directly caused by the negligent acts or omissions of Institution’s Indemnitees(s).

 

    	20

    	 

    

 

	6)	Subject
    to the limits and without waiving any immunities provided under applicable law (including constitutional provisions, statutes
    and case law) regarding the status, powers and authority of the Institution, the Institution’s principal (s), or Clinic,
    Institution and/or Clinic shall indemnify, hold harmless and defend Sponsor, its directors, officers, employees and agents,
    (“Sponsor’s Indemnitees”) from and against only those third-party Claims to the extent directly attributable
    to Institution’s and/or Clinic’s negligence in its conduct of the Study. Notwithstanding the above, Institution
    and Clinic shall have no obligation to indemnify Sponsor for any other Claims (including, but not limited to, infringement
    or product liability Claims).
	 	 
	7)	The
    indemnified party shall give notice to the indemnifying party promptly upon receipt of written notice of a Claim for which
    indemnification may be sought under this Agreement, provided, however, that failure to provide such notice shall not relieve
    indemnifying party of its indemnification obligations except to the extent that the indemnifying party’s ability to
    defend such Claim is materially, adversely affected by such failure. Indemnifying party shall not make any settlement admitting
    fault or incur any liability on the part of the indemnified party without indemnified Party’s prior written consent,
    such consent not to be unreasonably withheld or delayed. The indemnified Party shall cooperate with indemnifying Party in
    all reasonable respects regarding the defense of any such Claim, at indemnifying Party’s expense. The indemnified Party
    shall be entitled to retain counsel of its choice at its own expense. In the event a Claim falls under this indemnification
    clause, in no event shall the indemnified Party compromise, settle or otherwise admit any liability with respect to any Claim
    without the prior written consent of the indemnifying Party, and such consent not to be unreasonably withheld or delayed.
	 	 
	8)	EXCEPT
    FOR THE PARTIES’ OBLIGATIONS TO INDEMNIFY EACH OTHER AS STATED ABOVE IN THIS EXHIBIT C AND THE AGREEMENT, OR INCLUDED
    IN THE RESEARCH COLLABORATION AND SERVICES AGREEMENT, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR SPECIAL, CONSEQUENTIAL
    OR INCIDENTAL DAMAGES ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, EVEN IF ADVISED OF THE POSSIBILITY OF THE SAME.
	 	 
	9)	If
    a Study subject suffers an adverse reaction, illness, or injury which, in the reasonable judgment of Institution and/or Clinic,
    was directly caused by a Study Drug or Study Device or any properly performed procedures required by the Protocol, Sponsor
    shall reimburse for the reasonable and necessary costs of diagnosis and treatment of any Study subject injury, including hospitalization,
    but only to the extent such expenses are not attributable to: (i) Institution’s and/or Clinic’s negligence or
    willful misconduct; or (ii) the natural progression of an underlying or pre-existing condition or events, unless exacerbated
    by participating in the Study.
	 	 
	10)	Sponsor
    shall, at its sole cost and expense, procure and maintain commercial general liability insurance, clinical trial insurance
    and products liability insurance or equivalent self-insurance, unless otherwise indicated in an attachment, in amounts not
    less than $5,000,000.00 per occurrence and $5,000,000.00 annual aggregate. Such commercial general liability insurance, clinical
    trial insurance and products liability insurance or equivalent self-insurance shall provide contractual liability coverage
    for Sponsor’s indemnification obligations herein.
	 	 
	11)	Upon
    written request, Sponsor will provide evidence of its insurance policy or a program of self- insurance and will provide Institution
    with written notice of any material change in its coverage which would affect Sponsor’s ability to meet its obligations
    under this Agreement. Sponsor’s inability to meet its insurance obligation constitutes material breach of this L01
    and the Agreement executed with the CRO for this Study.

 

    	21

    	 

    

 

	12)	During
    the Study and for at least two (2) years following the completion of the Study at all sites, Sponsor shall promptly provide
    Institution and Principal Investigator with the written report of any findings, including Study results and any routine monitoring
    findings in site monitoring reports, and data safety monitoring committee reports including, but not limited to, data and
    safety analyses, and any Study information that may (i) affect the safety and welfare of current or former Study subjects,
    or (ii) influence the conduct of the Study. Institution and/or Principal Investigator will communicate findings to the IRB
    and Study subjects, as appropriate.
	 	 
	13	Except
    as permitted in Article 10.3 in the Agreement, neither Institution, Clinic, nor Sponsor may use the name, trademark, logo,
    symbol, or other image or trade name of any other party or their employees and agents in any advertisement, promotion, or
    other form of publicity or news release or that in any way implies endorsement without the prior written consent of an authorized
    representative of the other party whose name is being used. Such approval will not be unreasonably withheld.

 

The
authorized representatives have signed this Letter of Indemnification as set forth below,

 

	Providence Health & Services - Washington, dba	 	BriaCell Therapeutics Corp.
	Providence Regional medical Center Everett	 	 	 
	 	 	 	 	 
	By:		 	By:	
	Name:	Scott Combs	 	Name:	William V. Williams
	Title:	Chief Financial Officer	 	Title:	President and CEO
	Date:	9/28/18	 	Date:	2018 Oct 2

 

	The Everett Clinic, PLLC	 	Principal Investigator
	By:		 	By:	
	Name:	Albert
    W. Fisk, MD	 	Name:	Jason
    Lukas, MD
	Title:	Chief
    Medical Officer

    The Everett Clinic	 	Title:	 
	Date:	9/29/18	 	Date:	9/13/18

 

    	22

    	 

    

 

Exhibit
E

Itemized
Budget Between Institution and Clinic

 

    	23FIRST
SUPPLEMENT TO THE CLINICAL STUDY AGREEMENT

 

This
First Supplement to the Clinical Study Agreement (the “First Supplement”) is made on the last day of signature (the
“Effective Date”) and is made by and between Cancer Insight, LLC (“Cancer Insight”) and BriaCell Therapeutics
Corporation (“BriaCell”) (each a “Party” and collectively the “Parties”).

 

WHEREAS,
the Parties previously entered into a Clinical Study Agreement (the “Agreement”), executed on/around September 29,
2017 and pertaining to the study identified and described as “A Phase I/IIa Rollover Study of the Whole-Cell Vaccine BriaVaxTM
in Metastatic or Locally Recurrent Breast Cancer Patients in Combination with Ipilimumab or Pembrolizumab” (the “Study”);
and

 

WHEREAS,
the Parties desire to enter into this First Supplement to provide for an extension to the budget as a result of adding an additional
two Study sites to be managed and administered by Cancer Insight.

 

NOW,
THEREFORE, in consideration of the mutual promises contained herein, the Parties agree as follows:

 

	 	1.	The
    Parties agree to an additional amount of $332,817.66 (“First Extension Budget”) to be paid to Cancer Insight for
    two additional Study sites to be managed and administered by Cancer Insight.
	 	 	 
	 	1.	This
    First Extension Budget is to be considered as additional to the amounts agreed to in Exhibit B – Budget for Protocol
    of the Agreement.
	 	 	 
	 	2.	Payment
    shall be made to Cancer Insight based on an installment-based payment structure. Cancer Insight shall be paid $110,939.22,
    per fiscal quarter for a total of three (3) fiscal quarters. Unless otherwise agreed to in writing by the Parties, these payments
    shall be due on or before July 1, 2019, October 1, 2019, and January 1, 2020, respectively.
	 	 	 
	 	3.	Except
    as expressly supplemented and/or modified herein, all other terms, conditions, and provisions of the Agreement shall remain
    in full force and effect

 

    	Page 1 of 2

    	 

    

 

IN
WITNESS WHEREOF, the Parties have caused this First Supplement to be executed by their duly authorized representatives. This
First Supplement may be executed in one or more counterparts, each of which shall be deemed to be an original but all of which
together shall constitute one and the same instrument. Facsimile signatures, electronic signatures, and signatures transmitted
by email after having been scanned shall be accepted as originals for the purposes of this instrument.

 

	Cancer Insight, LLC	 	BriaCell Therapeutics Corp.
	 	 	 	 	 
	 	/s/ Steven White	 	 	/s/ William V. Williams
	 	 	 	 	 
	By:	Steven White	 	By:	William V. Williams
	 	 	 	 	 
	Title:	Chief Operating Officer	 	Title:	President and CEO
	 	 	 	 	 
	Date:	October 18, 2018	 	Date:	2018 October 19

 

 

    	Page 2 of 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]